AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry. Nevertheless, the company is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share.”
A number of other analysts have also weighed in on AMAG. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. ValuEngine upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Cowen and Company reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. BidaskClub lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, Deutsche Bank AG reiterated a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $24.00.
Shares of AMAG Pharmaceuticals (AMAG) traded up $0.45 on Wednesday, reaching $13.50. The company had a trading volume of 184,857 shares, compared to its average volume of 1,020,000. AMAG Pharmaceuticals has a 12 month low of $11.93 and a 12 month high of $36.83. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%. The company had revenue of $158.39 million during the quarter, compared to the consensus estimate of $158.83 million. During the same period last year, the company earned $1.45 earnings per share. AMAG Pharmaceuticals’s revenue was up 24.3% on a year-over-year basis. sell-side analysts anticipate that AMAG Pharmaceuticals will post -2.4 earnings per share for the current fiscal year.
WARNING: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2017/11/08/amag-pharmaceuticals-inc-amag-upgraded-to-hold-by-zacks-investment-research.html.
Several institutional investors have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $342,000. Macquarie Group Ltd. purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $266,000. 361 Capital LLC purchased a new position in shares of AMAG Pharmaceuticals during the third quarter valued at $197,000. Russell Investments Group Ltd. increased its stake in shares of AMAG Pharmaceuticals by 14.2% during the third quarter. Russell Investments Group Ltd. now owns 645,182 shares of the specialty pharmaceutical company’s stock valued at $11,903,000 after buying an additional 80,217 shares during the period. Finally, Municipal Employees Retirement System of Michigan increased its stake in shares of AMAG Pharmaceuticals by 58.8% during the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 4,870 shares during the period.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.